© Maddie Meyer/Getty Images
Moderna, based in Cambridge, Mass., has reached phase three trials for its coronavirus vaccine. At the same time, its executives have sold tens of millions of dollars worth of stock, which has led to intense criticism of the company.
Moderna, based in Cambridge, Mass., has reached phase three trials for its coronavirus vaccine. At the same time, its executives have sold tens of millions of dollars worth of stock, which has led to intense criticism of the company.
"On a scale of one to 10, one being less concerned and 10 being the most concerned," said Daniel Taylor, an associate professor of accounting at the Wharton School, "this is an 11."
Taylor said Moderna's stock-selling practices appear well outside the norm, and raise questions about the company's internal controls to prevent insider trading.
Comment: Mighty fishy indeed! Either these employees are complete newbs in the stock market and are selling as soon as they can profit, or they know something the rest of us only suspect - that this vaccine is going to be a dud at best or a complete disaster at worst.
See also: